Pharmaphorum
The EMA has started its review of Bayer’s asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J.
Pharmaphorum
The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J.
Pharmaphorum
The EMA has started its review of Bayer’s asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J.